Examples of using Sofosbuvir in Slovenian and their translations into English
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Financial
-
Computer
-
Official/political
-
Programming
v klinični študiji ALLY-1(AI444215, zdravilo Daklinza+ sofosbuvir+ ribavirin 12 tednov), vendar pa so bili deleži SVR manjši kot pri bolnikih s Child-Pugh A in B. Pri bolnikih s Child-Pugh C je tako priporočen konzervativen režim zdravljenja, to je zdravilo Daklinza+ sofosbuvir+/- ribavirin 24 tednov(glejte poglavji 4.2 in 5.1).
Daklinza+ sofosbuvir+ ribavirin for 12 weeks); however, SVR rates were lower than in patients with Child-Pugh A and B. Therefore, a conservative treatment regimen of Daklinza+ sofosbuvir+/- ribavirin for 24 weeks is proposed for patients with Child-Pugh C(see sections 4.2 and 5.1).Tednov OLYSIO+ sofosbuvir.
Weeks OLYSIO+ sofosbuvir.Tednov SMV+ sofosbuvir.
Weeks SMV+ sofosbuvir.Tednov simeprevir+ sofosbuvir.
Weeks simeprevir+ sofosbuvir.Zdravilna učinkovina je sofosbuvir.
The active substance is sofosbuvir.Daklatasvir+ sofosbuvir 12 tednov.
Daclatasvir+ sofosbuvir 12 weeks.Daklinza+ sofosbuvir 12 tednov.
Daklinza+ sofosbuvir for 12 weeks.Ali 12 tednov SMV+ sofosbuvir.
Or 12 weeks SMV+ sofosbuvir.Zdravilni učinkovini sta sofosbuvir in velpatasvir.
The active substances are sofosbuvir and velpatasvir.Zdravilni učinkovini sta ledipasvir in sofosbuvir.
The active substances are ledipasvir and sofosbuvir.Daklinza+ sofosbuvir+ ribavirin 12 tednov ali.
Daklinza+ sofosbuvir+ ribavirin for 12 weeks or.Daklinza+ sofosbuvir(brez ribavirina) 24 tednov.
Daklinza+ sofosbuvir(without ribavirin) for 24 weeks.Zdravilo Epclusa vsebuje zdravilni učinkovini sofosbuvir in velpatasvir.
Epclusa contains the active substances sofosbuvir and velpatasvir.Vsi ti bolniki so prejemali zdravilo Daklinza+ sofosbuvir+ ribavirin.
All of these patients received Daklinza+ sofosbuvir+ ribavirin.Daklinza+ sofosbuvir+ ribavirin 12 tednov(glejte poglavje 5.1).
Daklinza+ sofosbuvir+ ribavirin for 12 weeks(see section 5.1).Ali 24 tednov SMV+ sofosbuvir, brez ribavirina ali z ribavirinom4.
Or 24 weeks SMV+ sofosbuvir, with or without ribavirin4.V kliničnih farmakoloških študijah so sofosbuvir in GS-331007 spremljali zaradi farmakokinetičnih analiz.
In clinical pharmacology studies, both sofosbuvir and GS-331007 were monitored for purposes of pharmacokinetic analyses.izhodiščne lastnosti v študiji ALLY-2 daklatasvir+ sofosbuvir.
baseline characteristics in Study ALLY-2 daclatasvir+ sofosbuvir.Ledipasvir in sofosbuvir za nezdravljeno okužbo z genotipom 1 HCV// New Engl.
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.Bolnikov je prejemalo sofosbuvir+ ribavirin,
But 7 patients received sofosbuvir+ ribavirin
